Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin-4 and interleukin-18 production

Int Forum Allergy Rhinol. 2022 Oct;12(10):1313-1316. doi: 10.1002/alr.23003. Epub 2022 Apr 29.

¹ Department of Otolaryngology-Head & Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.
² Department of Otolaryngology-Head & Neck Surgery, University of Pittsburgh, Pittsburgh, PA.
³ Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, MA.
⁴ Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

No abstract available

Keywords: chronic rhinosinusitis; cytokine; dupilumab; nasal polyposis; type 2 inflammation.

Publication types